The Annals Visit the PharmaCE website!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 27, No. 3, pp. 285-289.
© 1993 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gearhart, M.
Right arrow Articles by Sorg, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gearhart, M.
Right arrow Articles by Sorg, T.

Research Articles

Foscarnet-induced severe hypomagnesemia and other electrolyte disorders

MO Gearhart and TB Sorg

OBJECTIVE: To report a case of possible foscarnet-induced severe hypomagnesemia and other electrolyte disorders. CASE SUMMARY: An AIDS patient experienced an exacerbation of cytomegalovirus retinitis and was treated with foscarnet. The patient experienced muscle twitches, tremulousness, and anxiety on day 17 of foscarnet therapy. Laboratory results indicated hypomagnesemia, hypocalcemia, hypokalemia, and hypophosphatemia. After electrolyte supplementation and discontinuation of foscarnet, the symptoms resolved and laboratory indices returned to normal. DISCUSSION: Electrolyte disorders associated with foscarnet are reviewed. Severe hypomagnesemia occurred in this patient and published literature is highlighted. In addition, known and/or possible mechanisms of the disorders are discussed. CONCLUSIONS: It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient. Electrolytes must be monitored frequently during foscarnet therapy. Also, concomitant therapy with antianxiety medications that may mask the symptoms of electrolyte disorders should be undertaken with caution.


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
D. H. Ellison
Renal magnification by EGF
Nephrol. Dial. Transplant., May 1, 2008; 23(5): 1497 - 1499.
[Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. L. Hammond, D. L. Koontz, H. Z. Bazmi, J. R. Beadle, S. E. Hostetler, G. D. Kini, K. A. Aldern, D. D. Richman, K. Y. Hostetler, and J. W. Mellors
Alkylglycerol Prodrugs of Phosphonoformate Are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations That Suppress Zidovudine Resistance
Antimicrob. Agents Chemother., June 1, 2001; 45(6): 1621 - 1628.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
M. M. Huycke, M. T. Naguib, M. M. Stroemmel, K. Blick, K. Monti, S. Martin-Munley, and C. Kaufman
A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection
Antimicrob. Agents Chemother., August 1, 2000; 44(8): 2143 - 2148.
[Abstract] [Full Text]

Home page
 NEJMHome page
F. J. Gennari
Hypokalemia
N. Engl. J. Med., August 13, 1998; 339(7): 451 - 458.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1993 by Harvey Whitney Books Company.